Gilead Sciences, Inc. $GILD Shares Sold by Miller Howard Investments Inc. NY

Miller Howard Investments Inc. NY lowered its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 654,778 shares of the biopharmaceutical company’s stock after selling 8,379 shares during the quarter. Gilead Sciences comprises about 2.4% of Miller Howard Investments Inc. NY’s holdings, making the stock its 9th largest position. Miller Howard Investments Inc. NY’s holdings in Gilead Sciences were worth $80,367,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Personal CFO Solutions LLC increased its stake in shares of Gilead Sciences by 1.7% during the 4th quarter. Personal CFO Solutions LLC now owns 4,572 shares of the biopharmaceutical company’s stock valued at $561,000 after acquiring an additional 76 shares during the last quarter. Moss Adams Wealth Advisors LLC increased its stake in shares of Gilead Sciences by 1.7% during the 4th quarter. Moss Adams Wealth Advisors LLC now owns 4,446 shares of the biopharmaceutical company’s stock valued at $546,000 after acquiring an additional 76 shares during the last quarter. SOA Wealth Advisors LLC. increased its stake in shares of Gilead Sciences by 8.7% during the 4th quarter. SOA Wealth Advisors LLC. now owns 1,016 shares of the biopharmaceutical company’s stock valued at $125,000 after acquiring an additional 81 shares during the last quarter. Trivium Point Advisory LLC increased its stake in shares of Gilead Sciences by 1.1% during the 3rd quarter. Trivium Point Advisory LLC now owns 7,325 shares of the biopharmaceutical company’s stock valued at $813,000 after acquiring an additional 83 shares during the last quarter. Finally, Greatmark Investment Partners Inc. increased its stake in shares of Gilead Sciences by 0.3% during the 4th quarter. Greatmark Investment Partners Inc. now owns 29,200 shares of the biopharmaceutical company’s stock valued at $3,584,000 after acquiring an additional 83 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on GILD. Oppenheimer upped their price objective on shares of Gilead Sciences from $128.00 to $165.00 and gave the company an “outperform” rating in a research note on Wednesday, February 11th. Citigroup upped their price objective on shares of Gilead Sciences from $156.00 to $165.00 and gave the company a “buy” rating in a research note on Monday, April 13th. Bank of America set a $162.00 price objective on shares of Gilead Sciences and gave the company a “buy” rating in a research note on Wednesday, February 11th. Wall Street Zen raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday, March 14th. Finally, Royal Bank Of Canada increased their target price on shares of Gilead Sciences from $118.00 to $123.00 and gave the stock a “sector perform” rating in a research report on Tuesday, April 7th. Twenty-four research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $157.35.

Insider Buying and Selling

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 115,640 shares of the company’s stock in a transaction that occurred on Friday, January 23rd. The stock was sold at an average price of $135.00, for a total value of $15,611,400.00. Following the completion of the transaction, the chief executive officer owned 566,698 shares in the company, valued at $76,504,230. This represents a 16.95% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $154.43, for a total value of $463,290.00. Following the completion of the transaction, the chief financial officer owned 167,779 shares of the company’s stock, valued at approximately $25,910,110.97. This represents a 1.76% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 299,280 shares of company stock worth $42,920,450 in the last 90 days. 0.30% of the stock is owned by insiders.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead received all required regulatory approvals to close its acquisition of Arcellx and extended the tender offer—this accelerates Gilead’s cell‑therapy/oncology strategy and reduces deal execution risk. Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer
• Positive Sentiment: Morgan Stanley raised its price target to $175 and kept an Overweight rating, signaling confidence in Gilead’s forward growth profile ahead of Q1 results. Morgan Stanley Adjusts Gilead Sciences, Inc. (GILD) Outlook Ahead of Q1 Earnings
• Positive Sentiment: High‑profile endorsements: Wells Fargo reiterated a Buy, and Jim Cramer said on-air he’d “hold on to it,” both supporting investor sentiment. Wells Fargo Sticks to Their Buy Rating for Gilead Sciences (GILD) Jim Cramer on Gilead Sciences: “I’d Hold On to It”
• Neutral Sentiment: Insider transactions: two insiders (including the CFO) sold small blocks under pre‑arranged 10b5‑1 plans—typical liquidity moves that are not clear signals of new company problems. Gilead Sciences (NASDAQ:GILD) Insider Sells $422,880.00 in Stock
• Neutral Sentiment: Goldman Sachs nudged its target modestly higher but kept a Neutral rating—mixed analyst signals leave upside expectations uneven. Goldman Sachs Adjusts Gilead Sciences Price Target to $130 from $125; Maintains Neutral Rating
• Neutral Sentiment: Upcoming quarterly earnings and recent analyst/valuation pieces are increasing attention and short‑term volatility as investors position around product trends and guidance. Gilead Sciences (GILD) Expected to Announce Quarterly Earnings on Thursday
• Negative Sentiment: RBC flagged weaker‑than‑expected persistence for Gilead’s recently launched HIV drug nine months after launch—this could temper upside to long‑term revenue assumptions for the franchise. Gilead Sciences’ HIV Drug Shows Weaker-Than-Expected Persistence Nine Months After Launch, RBC Says
• Negative Sentiment: Zacks trimmed Q1–Q4 FY2026 EPS estimates, lowering near‑term earnings expectations and adding downside risk to consensus. Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
• Negative Sentiment: Broad health‑care sector weakness is pressuring GILD alongside stock‑specific news, amplifying the intraday decline. Sector Update: Health Care Stocks Decline Late Afternoon

Gilead Sciences Price Performance

GILD opened at $137.64 on Monday. The firm has a 50 day moving average price of $144.35 and a 200 day moving average price of $131.56. The company has a market cap of $170.84 billion, a PE ratio of 20.33, a price-to-earnings-growth ratio of 1.82 and a beta of 0.39. Gilead Sciences, Inc. has a 1 year low of $93.37 and a 1 year high of $157.29. The company has a debt-to-equity ratio of 0.98, a quick ratio of 1.40 and a current ratio of 1.55.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.83 by $0.03. The firm had revenue of $7.93 billion during the quarter, compared to the consensus estimate of $7.68 billion. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The company’s revenue was up 4.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Sell-side analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, March 30th. Shareholders of record on Friday, March 13th were issued a $0.82 dividend. The ex-dividend date was Friday, March 13th. This represents a $3.28 dividend on an annualized basis and a yield of 2.4%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.79. Gilead Sciences’s dividend payout ratio (DPR) is currently 48.45%.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.